Defining and measuring negative symptoms of schizophrenia in clinical trials

European Neuropsychopharmacology

Volumn 24, Issue 5, 2014, Pages 737-743

  Marder, Stephen R ^a   Kirkpatrick, Brian ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Negative symptoms schizophrenia

Indexed keywords

ARTICLE; BRIEF NEGATIVE SYMPTOM SCALE; CLINICAL ASSESSMENT INTERVIEW FOR NEGATIVE SYMPTOMS; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL (TOPIC); CONSENSUS; DISEASE SEVERITY; HEALTH SURVEY; HUMAN; MEDICAL INFORMATION; NATIONAL HEALTH ORGANIZATION; NEGATIVE SYMPTOM ASSESSMENT SCALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHEDULE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

CLINICAL TRIALS AS TOPIC; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84899868447     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.10.016     Document Type: Article

References (30)

1. Alphs L., Morlock R., Coon C., Cazorla P., Szegedi A., Panagides J. Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia. Int. J. Methods Psychiatr. Res. 2011, 20(2):e31-37.
2. Alphs L., Morlock R., Coon C., van Willigenburg A., Panagides J. The 4-Item Negative Symptom Assessment (NSA-4) instrument: a simple tool for evaluating negative symptoms in schizophrenia following brief training. Psychiatry (Edgmont) 2010, 7(7):26-32.
3. Alphs L.D., Summerfelt A., Lann H., Muller R.J. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol. Bull. 1989, 25(2):159-163.
4. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry 1982, 39(7):784-788.
5. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry November 1989, (Suppl. 7):49-58.
6. Axelrod B.N., Goldman R.S., Alphs L.D. Validation of the 16-item Negative Symptom Assessment. J. Psychiatr. Res. 1993, 27(3):253-258.
7. Blanchard J.J., Cohen A.S. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr. Bull. 2006, 32(2):238-245.
8. Carpenter W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 1988, 145(5):578-583.
9. Daniel D.G., Alphs L., Cazorla P., Bartko J.J., Panagides J. Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor. Clin. Schizophr. Relat. Psychoses 2011, 5(2):87-94.
10. Fenton W.S., McGlashan T.H. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am. J. Psychiatry 1994, 151(3):351-356.
11. Gard D.E., Kring A.M., Gard M.G., Horan W.P., Green M.F. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr. Res. 2007, 93(1-3):253-260.
12. Horan W.P., Kring A.M., Gur R.E., Reise S.P., Blanchard J.J. Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr. Res. 2011, 132:140-145.
13. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
14. Kimhy D., Yale S., Goetz R.R., McFarr L.M., Malaspina D. The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr. Bull. 2006, 32(2):274-278.
15. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. The schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989, 30(2):119-123.
16. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 2001, 58(2):165-171.
17. Kirkpatrick B., Castle D., Murray R.M., Carpenter W.T. Risk factors for the deficit syndrome of schizophrenia. Schizophr. Bull. 2000, 26(1):233-242.
18. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):214-219.
19. Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.A., Daniel D.G., Cienfuegos A., Marder S.R. The brief negative symptom scale: psychometric properties. Schizophr. Bull. 2011, 37(2):300-305.
20. Kring A.M., Gur R.E., Blanchard J.J., Horan W.P., Reise S.P. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am. J. Psychiatry 2013, 170(2):165-172.
21. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58(12):538-546.
22. Messinger J.W., Tremeau F., Antonius D., Mendelsohn E., Prudent V., Stanford A.D., Malaspina D. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin. Psychol. Rev. 2011, 31(1):161-168.
23. Miller D.D., Arndt S., Andreasen N.C. Alogia, attentional impairment, and inappropriate affect: their status in the dimensions of schizophrenia. Compr. Psychiatry 1993, 34(4):221-226.
24. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
25. Strauss G.P., Frank M.J., Waltz J.A., Kasanova Z., Herbener E.S., Gold J.M. Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia. Biol. Psychiatry 2011, 69(5):424-431.
26. Strauss G.P., Horan W.P., Kirkpatrick B., Fischer B.A., Keller W.R., Miski P., Buchanan R.W., Green M.F., Carpenter W.T. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J. Psychiatr. Res. 2013, 47(6):783-790.
27. Strauss G.P., Keller W.R., Buchanan R.W., Gold J.M., Fischer B.A., McMahon R.P., Catalano L.T., Culbreth A.J., Carpenter W.T., Kirkpatrick B. Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr. Res. 2012, 142(1-3):88-92.
28. Tek C., Kirkpatrick B., Buchanan R.W. A five-year followup study of deficit and nondeficit schizophrenia. Schizophr. Res. 2001, 49(3):253-260.
29. Velligan D.I., Alphs L., Lancaster S., Morlock R., Mintz J. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009, 169(2):97-100.
30. Wynn J.K., Horan W.P., Kring A.M., Simons R.F., Green M.F. Impaired anticipatory event-related potentials in schizophrenia. Int. J. Psychophysiol. 2010, 77(2):141-149.